| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Descartes Paris V, Paris, France; and
INSERM CJF 94-11, Institut Gustave Roussy, Ville-Juif, France
The p53 protein is accumulated in tumor cells of many human cancers and can elicit in vivo humoral and proliferative responses. Rare reports about p53-mediated tumor recognition by CTLs have remained questioned. We therefore studied a panel of breast tumor and melanoma cell lines that we assayed for the presence of accumulated p53 and surface HLA-A2 and for the presentation of p53 epitopes. From PBMC of a healthy donor, we have generated a CTL line, D5/L9V, directed against HLA-A2-restricted peptide 264–272 from wild-type p53. It efficiently lysed breast adenocarcinomas MCF-7, MCF7/RA1, and MDA-MB-231, and melanoma M8, which all accumulate the p53 protein. Using competition assays, we made sure that tumor lysis by D5/L9V was due to recognition of endogenously produced p53 peptide 264–272 associated with the HLA-A2.1 molecule on the surface of these tumor cells. Cells with undetectable levels of wild-type p53, such as lymphoblastoid cells and melanoma M74, were not recognized by D5/L9V. Neither were breast tumor cell line MCF7/ADR nor melanoma line M44 because of HLA loss. This study therefore shows that it is possible to obtain in vitro CTL lines that specifically recognize a p53 epitope spontaneously presented by a variety of HLA-A2+ transformed cell lines provided they display abnormal patterns of p53 expression. This work points out that breast tumors and melanomas share a p53 epitope, and raises hopes for future immunotherapeutic approaches.
This article has been cited by other articles:
|
|
 |
|
  P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, H. J. Belmont, S. Price-Schiavi, B. Liu, H.-i. Lee, M. Fernandez, R. L. Wong, J. Builes, P. R. Rhode, and H. C. Wong Visualization of p53264-272/HLA-A*0201 Complexes Naturally Presented on Tumor Cell Surface by a Multimeric Soluble Single-Chain T Cell Receptor. J. Immunol., March 1, 2006; 176(5): 3223 - 3232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Carbone, I. F. Ciernik, M. J. Kelley, M. C. Smith, S. Nadaf, D. Kavanaugh, V. E. Maher, M. Stipanov, D. Contois, B. E. Johnson, et al. Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome J. Clin. Oncol., August 1, 2005; 23(22): 5099 - 5107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sirianni, P. K. Ha, M. Oelke, J. Califano, W. Gooding, W. Westra, T. L. Whiteside, W. M. Koch, J. P. Schneck, A. DeLeo, et al. Effect of Human Papillomavirus-16 Infection on CD8+ T-Cell Recognition of a Wild-Type Sequence p53264-272 Peptide in Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., October 15, 2004; 10(20): 6929 - 6937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ichiki, M. Takenoyama, M. Mizukami, T. So, M. Sugaya, M. Yasuda, T. So, T. Hanagiri, K. Sugio, and K. Yasumoto Simultaneous Cellular and Humoral Immune Response against Mutated p53 in a Patient with Lung Cancer J. Immunol., April 15, 2004; 172(8): 4844 - 4850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lomas, W. Liauw, D. Packham, K. Williams, A. Kelleher, J. Zaunders, and R. Ward Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy Ann. Onc., February 1, 2004; 15(2): 324 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Odunsi, A. A. Jungbluth, E. Stockert, F. Qian, S. Gnjatic, J. Tammela, M. Intengan, A. Beck, B. Keitz, D. Santiago, et al. NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential Targets for Immunotherapy in Epithelial Ovarian Cancer Cancer Res., September 15, 2003; 63(18): 6076 - 6083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tatsumi, C. J. Herrem, W. C. Olson, J. H. Finke, R. M. Bukowski, M. S. Kinch, E. Ranieri, and W. J. Storkus Disease Stage Variation in CD4+ and CD8+ T-Cell Reactivity to the Receptor Tyrosine Kinase EphA2 in Patients with Renal Cell Carcinoma Cancer Res., August 1, 2003; 63(15): 4481 - 4489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chikamatsu, A. Albers, J. Stanson, W. W. Kwok, E. Appella, T. L. Whiteside, and A. B. DeLeo p53110-124-specific Human CD4+ T-helper Cells Enhance in Vitro Generation and Antitumor Function of Tumor-reactive CD8+ T Cells Cancer Res., July 1, 2003; 63(13): 3675 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Azuma, S. Shichijo, Y. Maeda, T. Nakatsura, Y. Nonaka, T. Fujii, K. Koike, and K. Itoh Mutated p53 Gene Encodes a Nonmutated Epitope Recognized by HLA-B*4601-restricted and Tumor Cell-reactive CTLs at Tumor Site Cancer Res., February 15, 2003; 63(4): 854 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Smith, N. Dulphy, M. Salio, and V. Cerundolo Immunotherapy of colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 181 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hoffmann, A. D. Donnenberg, S. D. Finkelstein, V. S. Donnenberg, U. Friebe-Hoffmann, E. N. Myers, E. Appella, A. B. DeLeo, and T. L. Whiteside Frequencies of Tetramer+ T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in the Circulation of Patients with Head and Neck Cancer Cancer Res., June 1, 2002; 62(12): 3521 - 3529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. van der Burg, A. G Menon, A. Redeker, M.-C. Bonnet, J. W. Drijfhout, R. A. E. M. Tollenaar, C. J. H. van de Velde, P. Moingeon, P. J. K. Kuppen, R. Offringa, et al. Induction of p53-specific Immune Responses in Colorectal Cancer Patients Receiving a Recombinant ALVAC-p53 Candidate Vaccine Clin. Cancer Res., May 1, 2002; 8(5): 1019 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hoffmann, D. J. Loftus, K. Nakano, M. J. Maeurer, K. Chikamatsu, E. Appella, T. L. Whiteside, and A. B. DeLeo The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264-272 Epitope J. Immunol., February 1, 2002; 168(3): 1338 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Parajuli, V. Pisarev, J. Sublet, A. Steffel, M. Varney, R. Singh, D. LaFace, and J. E. Talmadge Immunization with Wild-Type p53 Gene Sequences Coadministered with Flt3 Ligand Induces an Antigen-specific Type 1 T-Cell Response Cancer Res., November 1, 2001; 61(22): 8227 - 8234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Keogh, J. Fikes, S. Southwood, E. Celis, R. Chesnut, and A. Sette Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity J. Immunol., July 15, 2001; 167(2): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jäger, E. Stockert, A. O. Güre, M. J. Scanlan, J. Karbach, E. Jäger, A. Knuth, L. J. Old, and Y.-T. Chen Identification of a Tissue-specific Putative Transcription Factor in Breast Tissue by Serological Screening of a Breast Cancer Library Cancer Res., March 1, 2001; 61(5): 2055 - 2061. [Abstract] [Full Text]
|
|
|
|
|
|
E. Yu. Nikitina, J. I. Clark, J. van Beynen, S. Chada, A. K. Virmani, D. P. Carbone, and D. I. Gabrilovich Dendritic Cells Transduced with Full-Length Wild-Type p53 Generate Antitumor Cytotoxic T Lymphocytes from Peripheral Blood of Cancer Patients Clin. Cancer Res., January 1, 2001; 7(1): 127 - 135. [Abstract] [Full Text]
|
|
|
|
|
|
T. K. Hoffmann, K. Nakano, E. M. Elder, G. Dworacki, S. D. Finkelstein, E. Appella, T. L. Whiteside, and A. B. DeLeo Generation of T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in Cancer Patients: Implications for Immunoselection of Epitope Loss Variants J. Immunol., November 15, 2000; 165(10): 5938 - 5944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. M. Vierboom, S. Zwaveling, G. M. J. Bos, M. Ooms, G. M. Krietemeijer, C. J. M. Melief, and R. Offringa High Steady-State Levels of p53 Are Not a Prerequisite for Tumor Eradication by Wild-Type p53-specific Cytotoxic T Lymphocytes Cancer Res., October 1, 2000; 60(19): 5508 - 5513. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Gnjatic, Y. Nagata, E. Jager, E. Stockert, S. Shankara, B. L. Roberts, G. P. Mazzara, S. Y. Lee, P. R. Dunbar, B. Dupont, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele PNAS, September 26, 2000; 97(20): 10917 - 10922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jager, Y. Nagata, S. Gnjatic, H. Wada, E. Stockert, J. Karbach, P. R. Dunbar, S. Y. Lee, A. Jungbluth, D. Jager, et al. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses PNAS, April 25, 2000; 97(9): 4760 - 4765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eura, K. Chikamatsu, F. Katsura, A. Obata, Y. Sobao, M. Takiguchi, Y. Song, E. Appella, T. L. Whiteside, and A. B. DeLeo A Wild-type Sequence p53 Peptide Presented by HLA-A24 Induces Cytotoxic T Lymphocytes that Recognize Squamous Cell Carcinomas of the Head and Neck Clin. Cancer Res., March 1, 2000; 6(3): 979 - 986. [Abstract] [Full Text]
|
|
|
|
|
|
X. Liu, E. A. Peralta, J. D. I. Ellenhorn, and D. J. Diamond Targeting of Human p53-overexpressing Tumor Cells by an HLA A*0201-restricted Murine T-Cell Receptor Expressed in Jurkat T Cells Cancer Res., February 1, 2000; 60(3): 693 - 701. [Abstract] [Full Text]
|
|
|
|
|
|
D. Jager, E. Stockert, M. J. Scanlan, A. O. Gure, E. Jager, A. Knuth, L. J. Old, and Y.-T. Chen Cancer-Testis Antigens and ING1 Tumor Suppressor Gene Product Are Breast Cancer Antigens: Characterization of Tissue-specific ING1 Transcripts and a Homologue Gene Cancer Res., December 1, 1999; 59(24): 6197 - 6204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Papadopoulos, C. S. Hesdorffer, N. Suciu-Foca, H. Hibshoosh, and P. E. Harris Wild-Type p53 Epitope Naturally Processed and Presented by an HLA-B Haplotype on Human Breast Carcinoma Cells Clin. Cancer Res., August 1, 1999; 5(8): 2089 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chikamatsu, K. Nakano, W. J. Storkus, E. Appella, M. T. Lotze, T. L. Whiteside, and A. B. DeLeo Generation of Anti-p53 Cytotoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells Clin. Cancer Res., June 1, 1999; 5(6): 1281 - 1288. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
